Drug therapy of attention deficit hyperactivity disorder: Current trends

Mens Sana Monographs

Volumn 10, Issue 1, 2012, Pages 45-69

  De Sousa, Avinash ^a   Kalra, Gurvinder ^b  

^a Desousa Foundation   (India)

^b Department of Psychiatry   (India)

Author keywords

agonists; ADHD; Antidepressants; Atomoxetine; Attention deficit hyperactivity disorder; Bupropion; Children; Clonidine; Dopamine; Drug delivery systems; Guanfacine; Lisdexamphetamine (LDX); Methylphenidate; Mixed Amphetamine Salts; Modafinil

Indexed keywords

EID: 84861311314     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.87261     Document Type: Review

References (139)

1. Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:841-5. PMID: 12921918. (Pubitemid 36966767)
2. Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: A community perspective. J Am Acad Child Adolesc Psychiatry 2000;39:975-84. PMID: 10939226. (Pubitemid 30639785)
3. Arabgol F, Paanaghi L, Hebrani P. Reboxetine versus Methylphenidate in the treatment of children and adolescents with ADHD. Eur Child Adolesc Psychiatry 2009;18:53-9. PMID: 18563471.
4. Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for the persistent use and compliance of immediate release methylphenidate: A 36 month naturalistic study. J Child Adolesc Psychopharmacol 2009;19: 673-81. PMID: 20035585.
5. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13(Suppl 1): 102-16. PMID: 15322961.
6. Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, et al. Efficacy and safety of atomoxetine in adolescents with attention deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007;17:407-20. PMID: 17822337.
7. Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, et al. Atomoxetine for the treatment of attention deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008;21(2):e314-20. PMID: 18245404. (Pubitemid 351198437)
8. Baptista-Neto L, Dodds A, Rao S, Whitney J, Torres A, Gonzalez-Heydrich J. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs 2008;17:77-84. PMID: 18095920. (Pubitemid 351578212)
9. Baranski JV, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 2004;19:323-32. PMID: 15252824. (Pubitemid 39106873)
10. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized double-blind placebocontrolled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;110:258-66. PMID: 12165576. (Pubitemid 34833008)
11. Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson K, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Pediatr Drugs 2003a;5:833-41. PMID: 14658924. (Pubitemid 38030609)
12. Biederman J, Faraone SV, Monuteaux MC, Plunkett EA, Gifford J, Spencer T. Growth deficits and attention-deficit/hyperactivity disorder revisited: Impact of gender, development and treatment. Pediatrics 2003;111(5 Pt 1):1010-6. PMID: 12728081. (Pubitemid 36542615)
13. Biederman J, Faraone SV. Attention deficit hyperactivity disorder: A worldwide concern. J Nerv Ment Dis 2004;192:453-4. PMID: 15232314. (Pubitemid 38918060)
14. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007a;62:970-6. PMID: 17631866. (Pubitemid 47562371)
15. Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychophramacology (Berl) 2007b;190:31-41. PMID: 17093981. (Pubitemid 44885341)
16. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008a;165:597-603. PMID: 18316421. (Pubitemid 351705336)
17. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD, CNS Spectr 2008b;13:1047-55. PMID: 19179940.
18. Boyle CA, Boulet S, Schieve LA, Cohen RA, Blumberg, SJ, Visser S, et al. Trends in the prevalence of developmental disabilities in the US 1997-2008. Pediatrics 2011;127:1034-42. PMID: 21606152.
19. Carlson GA, Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L, et al. A pilot study for augmenting atomoxetine with methylphenidate: Safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2007;1:p10-8. PMID: 17897473.
20. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta- analysis and meta-regression analysis. Psychopharmacology (Berl) 2007;194:197-209. PMID: 17572882. (Pubitemid 47457955)
21. Chazan R, Borowski C, Pianca T, Ludwig H, Rohde LA, Polanczyk G. Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention-deficit/hyperactivity disorder? A naturalistic study from a developing country. J Clin Psychopharmacol 2011;31:309-17. PMID: 21508864.
22. Cohen-Yahin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B. Efficacy of Reboxetine in the treatment of attention deficit hyperactivity diosrders in boys with intolerance to methylphenidate: An open 8 week methylphenidate controlled trial. Clin Neuropharmacol 2009;32(4):179-82. PMID: 19644227.
23. Cohen-Zion M, Ancoli-Israel S. Sleep in children with attention-deficit hyperactivity disorder: A review of naturalistic and stimulant intervention studies. Sleep Med Rev 2004;8:379-402. PMID: 15336238. (Pubitemid 39164487)
24. Connor DF, Edwards G, Fletcher KE, Baird J, Barkley RA, Steingard RJ. Correlates of comorbid psychopathology in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:193-200. PMID: 12544179. (Pubitemid 39610599)
25. Connor DF, Rubin J. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. Drugs Today (Barc) 2010;46:299-314. PMID: 20517532.
26. Cunningham CE, Boyle MH. Preschoolers at risk for attention-deficit hyperactivity disorder and oppositional defiant disorder: Family, parenting, and behavioral correlates. J Abnorm Child Psychol 2002;30:555-69. PMID: 12481971. (Pubitemid 38457415)
27. Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: Advantages, disadvantages and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009;48:240-8. PMID: 19242289.
28. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Bupropion sustained release in adolescents with comorbid attention-deficit/ hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001;40:307-14. PMID: 11288772. (Pubitemid 32179966)
29. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol 2004;14:65-73. PMID: 15142393. (Pubitemid 38525955)
30. Daviss WB, Perel JM, Rudolph GR, Axelson DA, Gilchrist R, Nuss S, et al. Steady-state pharmacokinetics of bupropion SR in juvenile patients. J Am Acad Child Adolesc Psychiatry 2005;44:349-57. PMID: 15782082. (Pubitemid 40393273)
31. Ding YS, Fowler JS, Volkow ND, Dewey SL, Wang GJ, Logan J, et al. Chiral drugs: comparison of the pharmacokinetics of [11C] d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 1997;131:71-8. PMID: 9181638. (Pubitemid 27242857)
32. Ding YS, Gatley SJ, Thanos PK, Shea C, Garza V, Xu Y, et al. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse 2004;53:168-75. PMID: 15236349. (Pubitemid 38971895)
33. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: An update. Pharmacotherapy 2009;29:656-79. PMID: 19476419.
34. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: Impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry 2001;40:508-15. PMID: 11349694. (Pubitemid 32374267)
35. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006;22:498-512. PMID : 17415287.
36. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for attention deficit hyperactivity disorder in children and adolescents using meta analyses. Eur Child Adolesc Psychiatry 2010;19:353-64. PMID: 19763664.
37. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry 2001;40:525-9. PMID: 11349696. (Pubitemid 32374269)
38. Findling RL. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: A review. Clin Ther 2008;30:942-57. PMID: 18555941. (Pubitemid 351799870)
39. Friedel S, Saar K, Sauer S, Dempfle A, Walitza S, Renner T, et al. Association and linkage of allelic variants of the dopamine transporter gene in ADHD. Mol Psychiatry 2007;12:923-33. PMID: 17579611. (Pubitemid 47482693)
40. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents, Paediatr Drugs 2009;11:203-26. PMID: 19445548.
41. Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 2007;46:1119-27. PMID: 17712235.
42. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003;348:553-6. PMID: 12571264. (Pubitemid 36159892)
43. Greenhill LL. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am 1992;15:1-27. PMID: 1347936.
44. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameters for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry 2002a;41(2 Suppl):26S-49S. PMID: 11833633.
45. Greenhill LL, Beyer DH, Finkleson J, Shaffer D, Biederman J, Conners CK, et al. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/Hyperactivity Disorder. J Atten Disord 2002b;6(Suppl 1):S89-100. PMID: 12685523.
46. Greenhill LL, Swanson JM, Steinhoff K, Fried J, Posner K, Lerner M, et al. A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:1234-41. PMID: 14560174. (Pubitemid 39592077)
47. Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:817-23. PMID: 16832318. (Pubitemid 43932908)
48. Greenhill LL, Posner K, Vaughan BS, Kratochvil CJ. Attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatr Clin N Am 2008;17:347-66. PMID: 18295150. (Pubitemid 351258353)
49. Guieu R, Couraud F, Pouget J. Adenosine and the nervous system: Clinical implications. Clin Neuropharmacol 1996;19:459-74. PMID: 8937786. (Pubitemid 26391352)
50. Halevy A, Shuper A. Methylphenidate induction of complex visual hallucinations. J Child Neurol 2009;24:1005-7. PMID: 19502578.
51. Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A review. Neuropsychiatr Dis Treat 2009a;5:215-26. PMID: 19557116.
52. Hammerness P, Doyle R, Kotarski M, Georgiopoulos A, Joshi G, Zeitlin S. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: A prospective open-label study. Eur Child Adolesc Psychiatry 2009b;18:493-8. PMID: 19377865.
53. Hechtman L. Treatment of attention deficit hyperactivity disorder in patients unresponsive to stimulants. J Psych Neurosci 2011;36:216-8. PMID: 21496443
54. Hermens DF, Rowe DL, Gordon E, Williams LM. Integrative neuroscience approach to predict ADHD stimulant response. Expert Rev Neurother 2006;6:753-63. PMID: 16734523. (Pubitemid 43961879)
55. Jaanus SD. Ocular side-effects of selected systemic drugs. Optom Clin 1992;2:73-96. PMID: 1363080.
56. Kashani J, Ruha AM. Isolated atomoxetine overdose resulting in seizure. J Emerg Med 2007;32:175-8. PMID: 17307628. (Pubitemid 46329316)
57. Keenan K, Wakschlag LS. More than the terrible twos: the nature and severity of behavioural problems in clinic-referred preschool children. J Abnorm Child Psychol 2000;28:33-46. PMID: 10772348. (Pubitemid 30179911)
58. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of morning and evening behavior: A double-blind placebo-controlled trial, Pediatrics 2004;114:e1-8. PMID: 15231966.
59. Kollins S, Greenhill LL, Swanson J, Wigal S, Abikoff H, McCracken J, et al. Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry 2006;45:1275-83. PMID: 17023869. (Pubitemid 44665444)
60. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:919-27. PMID: 16865034. (Pubitemid 44126866)
61. Kratochvil CJ, Vaughan BS, Mayfield-Jorgensen ML, March JS, Kollins SH, Murray DW, et al. A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:175-85. PMID: 17489712. (Pubitemid 46828913)
62. Kratochvil, CJ, Vaughan BS, Stoner JA, Daughton JM, Lubberstedt BD, Murray DW, et al. A double blind placebo controlled trial of atomoxetine in young children with attention deficit hyperactivity disorder. Pediatrics 2011;127:862-8. PMID: 21422081.
63. Kurlan R. Tourette's syndrome: are stimulants safe? Curr Neurol Neurosci Rep 2003;3:285-8. PMID: 12930697. (Pubitemid 38899013)
64. Ledbetter M. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol 2005;15:331-3. PMID: 15910218. (Pubitemid 40734113)
65. Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML. Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm 2007;13(9 Suppl B):S2-13. PMID: 18062734.
66. Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: Prospective follow-up into adulthood. Am J Psychiatry 2008;165:604-9. PMID: 18381904. (Pubitemid 351705337)
67. March JS. The Preschool ADHD Treatment Study (PATS) as the culmination of 20 years of clinical trials in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2011;50:427-30. PMID: 21515189.
68. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: Recent advances in paediatric pharmacotherapy. Drugs 2010;70:15-40. PMID: 20030423.
69. McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:530-8. PMID: 15908835. (Pubitemid 40720952)
70. McBurnett K, Starr HL. OROS Methylphenidate for adult patients with attention deficit hyperactivity disorder. Exp Opin Pharmacother 2011;12:315-24. PMID: 21226641.
71. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 2005;57:1367-73. PMID: 15950009. (Pubitemid 40798556)
72. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil CJ, et al. Once daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized placebo controlled study. Am J Psychiatry 2002;159:1896-901. PMID: 12411225. (Pubitemid 35283256)
73. Mikami AY, Cox DJ, Davis MT, Wilson K, Merkel RL, Burket R. Sex differences in the efficacy of extended release methylphenidate among adolescents with ADHD. J Clin Psychol Med Settings 2009;16:233-42. PMID: 19418208.
74. Mohammadi MR, Ghanizadeh A, Alaghband-Rad J, Tehranidoost M, Mesgarpour B, Soori H. Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder in children and adolescents in a double-blind, randomized clinical trial. J Child Adolesc Psychopharmacol 2004a;14:418-25. PMID: 15650498. (Pubitemid 39473127)
75. Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: A pilot double-blind randomized trial. J Clin Pharm Ther 2004b;29:139-44. PMID: 15068402. (Pubitemid 38482478)
76. Murray DW. Treatment of pre-schoolers with attention-deficit/ hyperactivity disorder. Curr Psychiatry Rep 2010;12:374-81. PMID: 20676944.
77. Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of damphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther 2009;31:142-76. PMID: 19243715.
78. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment, Pediatrics 2004;113:762-9. PMID: 15060225.
79. Narahashi T, Moriguchi S, Zhao X, Marszalec W, Yeh JZ. Mechanisms of action of cognitive enhancers on neuroreceptors. Biol Pharm Bull 2004;27):1701-6. PMID: 15516710. (Pubitemid 41701591)
80. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. Am J Psychiatry 2008;165:721-30. PMID: 18281409. (Pubitemid 351810541)
81. Párraga HC, Párraga MI, Harris DK. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med 2007;37:415-24. PMID: 18441629. (Pubitemid 351468864)
82. Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 1997;12:527-46. [ABSTRACT[ [FULL TEXT[ [PUBMED[ (Pubitemid 28049993)
83. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:E105. PMID: 11389303.
84. Pelham WE, Manos MJ, Ezzell CE, Tresco KE, Gnagy EM, Hoffman MT, et al. A dose ranging study of methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:522-9. PMID: 15908834. (Pubitemid 40720951)
85. Pelham WE Jr, Fabiano GA. Evidence-based psychosocial treatment for attention-deficit/hyperactivity disorder: An update. J Clin Child Adolesc Psychol 2008;37:184-214. PMID: 18444058.
86. Perrin JM, Friedman RA, Knilans TK; Black Box Working Group, Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008;122:451-3. PMID: 18676566.
87. Pliszka SR, Browne RG, Olvera RL, Wynne SK. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2000;39:619-26. PMID: 10802980. (Pubitemid 30238831)
88. Polzer J, Bangs ME, Zhang S, Dellva MA, Tauscher-Wisniewski S, Acharya N, et al. Metaanalysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. Biol Psychiatry 2007;61:713-9. PMID: 16996485. (Pubitemid 46328864)
89. Popovic B, Bhattacharya P, Sivaswamy L. Lisdexamfetamine: A prodrug for the treatment of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm 2009;66:2005-12. PMID: 19890083.
90. Posner K, Melvin GA, Murray DW, Gugga SS, Fisher P, Skrobala A, Cunningham C, et al. Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/ Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007;17:547-62. PMID: 17979577. (Pubitemid 350058985)
91. Potter AS, Newhouse PA. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2004;176:182-94. PMID: 15083253. (Pubitemid 39517948)
92. Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: A systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996;35:599-605. PMID: 8935206. (Pubitemid 26134797)
93. Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: Update on new stimulant preparations, atomoxetine and novel treatments. Child Adolesc Psychiatr Clin N Am 2006;15:13-50. PMID: 16321724. (Pubitemid 41735237)
94. Pringsheim T, Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011;4:CD007990. PMID: 21491404.
95. Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, et al. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary tolerability and efficacy study. Clin Ther 2007;29:1168-77. PMID: 17692731. (Pubitemid 47198889)
96. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate: A review of height/weight, cardiovascular and somatic complaint side effects. Clin Psychol Rev 2002;22:1107-31. PMID: 12436807.
97. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005;44:428-33. PMID: 15843764. (Pubitemid 40559690)
98. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 2001;49:258-67. PMID: 11230877.
99. Safer DJ, Zito JM, Gardner JE. Pemoline hepatotoxicity and post marketing surveillance. J Am Acad Child Adolesc Psychiatry 2001;40:622-9. PMID: 11392339. (Pubitemid 32473375)
100. Sallee FR, Stiller RL, Perel JM. Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1992;31:244-51. PMID: 1564025.
101. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:215-26. PMID: 19519256.
102. Sallee FR. The role of alpha-2-adrenergic agonists in attention-deficit/hyperactivity disorder. Postgrad Med 2010;122:78-87. PMID: 20861591.
103. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: A retrospective and prospective effectiveness study. Child Care Health Dev 2006;32:575-83. PMID: 16919137. (Pubitemid 44210096)
104. Sears J, Patel NC. Development of tics in a thirteen-year-old male following atomoxetine use. CNS Spectr 2008;13:301-3. PMID: 18408649. (Pubitemid 351656251)
105. Shastri PC, Shastri J, Shastri DJ. Research in child and adolescent psychiatry in India. Indian J Psychiatry 2010;52:219-23. PMID: 21836681.
106. Sitholey P, Agarwal V, Chamoli S. A preliminary study of factors affecting adherence to medication in clinic children with attention deficit hyperactivity disorder. Indian J Psychiatry 2011;53:41-4. PMID: 21431007.
107. Silva R, Tilker HA, Cecil JT, Kovalik S, Khetani V, Faleck H, et al. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2004;14:555-63. PMID: 21431007.
108. Simpson D, Plosker GL. Atomoxetine: A review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004;64:205-22. PMID: 14717619. (Pubitemid 38186965)
109. Sonuga-Barke EJ, Daley D, Thompson M, Swanson J. Preschool ADHD: Exploring uncertainties in diagnostic validity and utility, and treatment efficacy and safety. Expert Rev Neurother 2003;3:465-76. PMID: 19810931. (Pubitemid 36890051)
110. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:251-65. PMID: 11642475. (Pubitemid 32937637)
111. Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, et al. Effect of atom oxetine on growth in children with attention-deficit/ hyperactivity disorder following upto five years of treatment. J Child Adolesc Psychopharmacol 2007;17:689-700. PMID: 17979588.
112. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:501-10. PMID: 19877974.
113. Spiller HA, Lintner CP, Winter ML. Atomoxetine ingestions in children: A report from poison centers. Ann Pharmacother 2005;39:1045-48. PMID: 15870137. (Pubitemid 40695971)
114. Steele M, Ricardelli R, Binder C. Effectiveness of OROS methylphenidate versus usual care with immediate release methylphenidate in ADHD children. Paper presented at the American Psychiatric Society Annual Meeting, New York (NY), May 1st to 6th; 2004.
115. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003;112:e404. PMID: 14595084.
116. Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 2008;17:475-90. PMID: 18295157. (Pubitemid 351265399)
117. Stiefel G, Besag FM. Cardiovascular side effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention deficit hyperactivity disorder. Drug Safety 2010;33:821-42. PMID: 20812768.
118. Swanson J, Kinsbourne M, Roberts W, Zucker K. Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 1978;61:21-9. PMID: 400817. (Pubitemid 8268787)
119. Swanson JM, Lerner M, Wigal T, Steinhoff K, Greenhill L, Posner K, et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 2002;6(suppl 1):S73-88. PMID: 12685522.
120. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11. PMID: 12578439. (Pubitemid 36173129)
121. Swanson J, Baler RD, Volkow ND. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: A decade of progress. Neuropsychopharmacology 2011;36:207-26. PMID: 20881946.
122. Tjon Pian Gi CV, Broeren JP, Starreveld JS, Versteegh FG. Melatonin for the treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: A preliminary open label study. Eur J Pediatr 2003;162:554-5. PMID: 12783318. (Pubitemid 36904296)
123. Upadhyaya HP, Brady KT, Wang W. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: A pilot study. J Am Acad Child Adolesc Psychiatry 2004;43:199-205. PMID: 14726727.
124. Vitiello B. Psychopharmacology for young children: Clinical needs and research opportunities. Pediatrics 2001;108983-9. PMID: 11581454.
125. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: Insights from PET imaging studies. J Atten Disord 2002;6(Suppl 1):S31-43. PMID: 12685517.
126. Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial. Aust N Z J Psychiatry 2007;41:222-30. PMID: 17464703. (Pubitemid 46705737)
127. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:647-55. PMID: 15968233. (Pubitemid 40875359)
128. Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007;49(7):498-502. PMID: 17593120. (Pubitemid 47018494)
129. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, et al. A double-blind, placebocontrolled trial of dexmethylphenidate and d,l-threo-methylphenidate in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:1406-14. PMID: 15502600. (Pubitemid 39411041)
130. Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005;9:275-89. PMID: 16371674. (Pubitemid 41551759)
131. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23(Suppl 1):21-31. PMID: 19621975.
132. Wilens TE, Biederman J, Wong J, Spencer TJ, Prince JB. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol 2000;10:217-22. PMID: 11052411.
133. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long term open-label study. J Am Acad Child Adolesc Psychiatry 2003a;42:424-33. PMID: 12649629. (Pubitemid 39625077)
134. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attentiondeficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003b;111:179-85. PMID: 12509574. (Pubitemid 36071051)
135. Wilens TE, Biederman J, Lerner M; Concerta Study Group. Effects of once-daily osmoticrelease methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: Results from a one-year follow-up study. J Clin Psychopharmacol 2004;24:36-41. PMID: 14709945. (Pubitemid 38134164)
136. Wilens TE, Haight BR, Horrigan JP, Hudziak JJ, Rosenthal NE, Connor DF, et al., Buproprion XL in adults with attention-deficit/hyperactivity disorder: A randomized placebo-controlled study. Biol Psychiatry 2005;57:793-801. PMID: 15820237. (Pubitemid 40487924)
137. Wolraich ML, Lindgren S, Stromquist A, Milich R, Davis C, Watson D. Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder. Pediatrics 1990;86:95-101. PMID: 2359688. (Pubitemid 20198465)
138. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:883-92. PMID: 11581440. (Pubitemid 32947657)
139. Wolraich ML, Bard DE, Stein MT, Rushton JL, O'Connor KG. Pediatrician's attitudes and practice on ADHD before and after the development of ADHD practice guidelines. J Atten Disord 2010;13:563-72. PMID: 19706877.